LCI133 [CAS 3065284-87-6]

LCI133 is afirst-in-class, nanomolar-potent, selective multikinase inhibitor targeting CDK4/6/9 and AURKA/B (IC50 = 4.7/10.2/4.1 nM and 2.8/10.6 nM) . LCI133 induces S/G2 cell-cycle arrest and robust apoptosis in MYCN-amplified neuroblastoma BE (2) -C cells. LCI133 demonstrates significant antitumor efficacy in a BE (2) -C neuroblastoma xenograft model[1].

[3065284-87-6]

C33H34N6O4

578.66

CN(C(C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)C5=CC6=C(C(C=C(O6)N7CCOCC7)=O)C=C5)=O)C

Aurora Kinase; CDK

Aurora A; Aurora B; CDK4; CDK6; CDK9

Room temperature